(HSIC) Henry Schein - Overview
Sector: Healthcare | Industry: Medical Distribution | Exchange: NASDAQ (USA) | Market Cap: 8.724m USD | Total Return: 7.3% in 12m
Avg Turnover: 106M
EPS Trend: -49.9%
Qual. Beats: 1
Rev. Trend: 80.1%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Henry Schein, Inc. (HSIC) is a global distributor of health care products and services, primarily serving office-based dental and medical practitioners. The company operates through three core segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. Its portfolio includes consumable merchandise, equipment, surgical products, and practice management software.
The company utilizes a hub-and-spoke distribution model to manage high volumes of low-cost consumable goods alongside high-value capital equipment. As a leader in the Health Care Distributors sub-industry, Henry Schein benefits from the fragmented nature of the dental market, where practitioners often rely on single-source providers for both physical supplies and digital integration tools.
Investors can evaluate the companys historical performance and valuation metrics on ValueRay.
Founded in 1932 and headquartered in Melville, New York, the firm has expanded its reach to include government institutions, ambulatory surgery centers, and physician practices. By manufacturing its own branded consumables and specialty products like dental implants, the company captures additional margin across the medical supply chain.
- Global dental procedure volume and consumable sales drive consistent revenue growth
- High-margin specialty products like dental implants and orthodontics expand operating margins
- Practice management software adoption increases recurring revenue and customer retention
- Consolidation of independent dental practices impacts distribution channel pricing power
- Cybersecurity vulnerabilities and data breaches pose significant operational and reputational risks
| Net Income: 395.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.13 > 1.0 |
| NWC/Revenue: 8.96% < 20% (prev 8.84%; Δ 0.12% < -1%) |
| CFO/TA 0.05 > 3% & CFO 578.0m > Net Income 395.0m |
| Net Debt (3.95b) to EBITDA (995.0m): 3.97 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (116.1m) vs 12m ago -7.04% < -2% |
| Gross Margin: 29.69% > 18% (prev 29.62%; Δ 0.08% > 0.5%) |
| Asset Turnover: 122.9% > 50% (prev 120.9%; Δ 1.99% > 0%) |
| Interest Coverage Ratio: 4.48 > 6 (EBIT TTM 690.0m / Interest Expense TTM 154.0m) |
| A: 0.11 (Total Current Assets 4.50b - Total Current Liabilities 3.30b) / Total Assets 11.3b |
| B: 0.29 (Retained Earnings 3.29b / Total Assets 11.3b) |
| C: 0.06 (EBIT TTM 690.0m / Avg Total Assets 10.9b) |
| D: 0.50 (Book Value of Equity 3.27b / Total Liabilities 6.48b) |
| Altman-Z'' = 2.60 = A |
| DSRI: 1.03 (Receivables 1.72b/1.58b, Revenue 13.4b/12.7b) |
| GMI: 1.00 (GM 29.62% / 29.69%) |
| AQI: 0.97 (AQ_t 0.52 / AQ_t-1 0.53) |
| SGI: 1.06 (Revenue 13.4b / 12.7b) |
| TATA: -0.02 (NI 395.0m - CFO 578.0m) / TA 11.3b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of June 04, 2026, the stock is trading at USD 75.74 with a total of 1,143,479 shares traded.
Over the past week, the price has changed by +0.09%,
over one month by +5.17%,
over three months by -5.57% and
over the past year by +7.33%.
Henry Schein has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold HSIC.
- StrongBuy: 3
- Buy: 4
- Hold: 8
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 87.2 | 15.1% |
P/E Trailing = 23.136
P/E Forward = 14.3062
P/S = 0.6518
P/B = 2.6707
P/EG = 1.6838
Revenue TTM = 13.4b USD
EBIT TTM = 690.0m USD
EBITDA TTM = 995.0m USD
Long Term Debt = 2.33b USD (from longTermDebt, last quarter)
Short Term Debt = 1.16b USD (from shortTermDebt, last quarter)
Debt = 4.09b USD (from shortLongTermDebtTotal, last quarter) + Leases 341.0m
Net Debt = 3.95b USD (calculated: Debt 4.09b - CCE 138.0m)
Enterprise Value = 12.7b USD (8.72b + Debt 4.09b - CCE 138.0m)
Interest Coverage Ratio = 4.48 (Ebit TTM 690.0m / Interest Expense TTM 154.0m)
EV/FCF = 29.41x (Enterprise Value 12.7b / FCF TTM 431.0m)
FCF Yield = 3.40% (FCF TTM 431.0m / Enterprise Value 12.7b)
FCF Margin = 3.22% (FCF TTM 431.0m / Revenue TTM 13.4b)
Net Margin = 2.95% (Net Income TTM 395.0m / Revenue TTM 13.4b)
Gross Margin = 29.69% ((Revenue TTM 13.4b - Cost of Revenue TTM 9.41b) / Revenue TTM)
Gross Margin QoQ = 31.77% (prev 28.92%)
Tobins Q-Ratio = 1.12 (Enterprise Value 12.7b / Total Assets 11.3b)
Interest Expense / Debt = 3.77% (Interest Expense 154.0m / Debt 4.09b)
Taxrate = 23.58% (129.0m / 547.0m)
NOPAT = 527.3m (EBIT 690.0m * (1 - 23.58%))
Current Ratio = 1.36 (Total Current Assets 4.50b / Total Current Liabilities 3.30b)
Debt / Equity = 1.25 (Debt 4.09b / totalStockholderEquity, last quarter 3.27b)
Debt / EBITDA = 3.97 (Net Debt 3.95b / EBITDA 995.0m)
Debt / FCF = 9.17 (Net Debt 3.95b / FCF TTM 431.0m)
Total Stockholder Equity = 3.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.63% (Net Income 395.0m / Total Assets 11.3b)
RoE = 11.86% (Net Income TTM 395.0m / Total Stockholder Equity 3.33b)
RoCE = 12.20% (EBIT 690.0m / Capital Employed (Equity 3.33b + L.T.Debt 2.33b))
RoIC = 5.84% (NOPAT 527.3m / Invested Capital 9.03b)
WACC = 6.72% (E(8.72b)/V(12.8b) * Re(8.52%) + D(4.09b)/V(12.8b) * Rd(3.77%) * (1-Tc(0.24)))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -100.00 | Cagr: -5.16%
[DCF] Terminal Value 73.10% ; FCFF base≈465.8m ; Y1≈408.5m ; Y5≈330.0m
[DCF] Fair Price = 11.81 (EV 5.30b - Net Debt 3.95b = Equity 1.35b / Shares 113.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -49.94 | EPS CAGR: -4.25% | SUE: 0.99 | # QB: 1
Revenue Correlation: 80.05 | Revenue CAGR: 2.15% | SUE: 0.34 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.23 | Chg30d=+1.07% | Revisions=+18% | Analysts=15
EPS next Quarter (2026-09-30): EPS=1.37 | Chg30d=-3.86% | Revisions=-75% | Analysts=15
EPS current Year (2026-12-31): EPS=5.34 | Chg30d=+0.56% | Revisions=+41% | GrowthEPS=+7.5% | GrowthRev=+4.3%
EPS next Year (2027-12-31): EPS=5.91 | Chg30d=+0.40% | Revisions=+38% | GrowthEPS=+10.5% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: -75%